Naloxone

Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias[1].

Product Specifications

CAS Number

[465-65-6]

UNSPSC

12352005

Hazard Statement

H302

Target

Opioid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/naloxone.html

Purity

99.71

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(O2)C([C@]([C@]2([H])C(CC3)=O)(CCN4CC=C)[C@]3(O)[C@H]4C5)=C5C=C1

Molecular Formula

C19H21NO4

Molecular Weight

327.37

Precautions

H302

References & Citations

[1]McIntosh TK, et al. Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat. J Neurotrau|[2]Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21 (5) :804-814.|[3]Izquierdo I, et al. Effect of ACTH, epinephrine, beta-endorphin, naloxone, and of the combination of naloxone or beta-endorphinwith ACTH or epinephrine on memory consolidation. Psychoneuroendocrinology. 1983;8 (1) :81-7.|[4]Soteropoulos GC, et al. Neuromuscular effects of morphine and naloxone. J Pharmacol Exp Ther. 1973 Jan;184 (1) :136-42.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light, stored under nitrogen)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Nature. 2025 Dec;648 (8094) :755-763.|Br J Pharmacol. 2025 Jul 21.|Cell Rep. 2020 Mar 17;30 (11) :3625-3631.e6. |Eur J Pain. 2017 May;21 (5) :804-814.|Nat Commun. 2025 Aug 1;16 (1) :7074.